Reversal of TGF-β-induced epithelial–mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor

The epithelial–mesenchymal transition (EMT) is considered an essential process for cancer development and metastasis. Sorafenib, a RAF kinase and VEGFR-2 inhibitor, exhibits efficacy against advanced hepatocellular carcinoma (HCC), renal carcinoma, and thyroid cancer. It is well established that tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Modi, Siddharth J., Tiwari, Anshuly, Kulkarni, Vithal M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663974/
https://www.ncbi.nlm.nih.gov/pubmed/34909649
http://dx.doi.org/10.1016/j.crphar.2021.100014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663974/
https://www.ncbi.nlm.nih.gov/pubmed/34909649
http://dx.doi.org/10.1016/j.crphar.2021.100014

Ejemplares similares